This study is currently not recruiting participants.

A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors Leukemias and Myeloproliferative Neoplasms

Study on Investigational Treatment for Diabetes

Not Recruiting
1 years - 21 years
All
Phase N/A

Brief description of study.

No Description Available

Detailed description of study

No Description Available

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Solid Tumors Leukemias, Myeloproliferative Neoplasms
  • Age: 1 years - 21 years
  • Gender: All
  • Who can participate: Adults aged 18-65 with a diagnosis of type 2 diabetes may be eligible to participate. Key eligibility factors include stable medication doses for at least three months and no history of severe cardiovascular events.
  • Study details: Participants will be randomly assigned to receive either the investigational treatment or a placebo. They will be monitored for changes in blood sugar levels and other health indicators throughout the study.
Updated on 19 Feb 2024. Study ID: 1105005280

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team